Area of research
Hematology · Oncology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research, CAR-T cell therapy research, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Clonal Hematopoiesis in Young Women Treated for Breast Cancer
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of <i>KMT2A</i>-r and <i>NPM1c</i> AML
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein
Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasms
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state
Functional dissection of inherited non-coding variation influencing multiple myeloma risk
Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19
Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Association of clonal hematopoiesis with chronic obstructive pulmonary disease
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216
Modeling and targeting of erythroleukemia by hematopoietic genome editing
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Small-molecule-induced polymerization triggers degradation of BCL6
Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade
Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis
Identification of germline variants in adults with hemophagocytic lymphohistiocytosis